Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2004 Sep 2;63(12):1594–1600. doi: 10.1136/ard.2004.020875

Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis

A Calin 1, B Dijkmans 1, P Emery 1, M Hakala 1, J Kalden 1, M Leirisalo-Repo 1, E Mola 1, C Salvarani 1, R Sanmarti 1, J Sany 1, J Sibilia 1, J Sieper 1, S van der Linden 1, E Veys 1, A Appel 1, S Fatenejad 1
PMCID: PMC1754832  PMID: 15345498

Abstract

Objective: A double blind, randomised, placebo controlled study to evaluate the safety and efficacy of etanercept to treat adult patients with ankylosing spondylitis (AS).

Methods: Adult patients with AS at 14 European sites were randomly assigned to 25 mg injections of etanercept or placebo twice weekly for 12 weeks. The primary efficacy end point was an improvement of at least 20% in patient reported symptoms, based on the multicomponent Assessments in Ankylosing Spondylitis (ASAS) response criteria (ASAS 20). Secondary end points included ASAS 50 and ASAS 70 responses and improved scores on individual components of ASAS, the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), acute phase reactants, and spinal mobility tests. Safety was evaluated during scheduled visits.

Results: Of 84 patients enrolled, 45 received etanercept and 39 received placebo. Significantly more etanercept patients than placebo patients responded at the ASAS 20 level as early as week 2, and sustained differences were evident up to week 12. Significantly more etanercept patients reported ASAS 50 responses at all times and ASAS 70 responses at weeks 2, 4, and 8; reported lower composite and fatigue BASDAI scores; had lower acute phase reactant levels; and had improved spinal flexion. Etanercept was well tolerated. Most adverse events were mild to moderate; the only between-group difference was injection site reactions, which occurred significantly more often in etanercept patients.

Conclusions: Etanercept is a well tolerated and effective treatment for reducing clinical symptoms and signs of AS.

Full Text

The Full Text of this article is available as a PDF (90.6 KB).

Figure 1.

Figure 1

Open in a new tab

 (A) Achievement of ASAS 20, by treatment group; (B) achievement of ASAS 50, by treatment group; (C) achievement of ASAS 70, by treatment group.

Figure 2.

Figure 2

Open in a new tab

 Percentage of patients with BASDAI scores <40.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abuzakouk M., Feighery C., Jackson J. Tumour necrosis factor blocking agents: a new therapeutic modality for inflammatory disorders. Br J Biomed Sci. 2002;59(3):173–179. doi: 10.1080/09674845.2002.11783656. [DOI] [PubMed] [Google Scholar]
  2. Anderson J. J., Baron G., van der Heijde D., Felson D. T., Dougados M. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum. 2001 Aug;44(8):1876–1886. doi: 10.1002/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO;2-F. [DOI] [PubMed] [Google Scholar]
  3. Arend William P. The mode of action of cytokine inhibitors. J Rheumatol Suppl. 2002 Sep;65:16–21. [PubMed] [Google Scholar]
  4. Baert Filip, Noman Maja, Vermeire Severine, Van Assche Gert, D' Haens Geert, Carbonez An, Rutgeerts Paul. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003 Feb 13;348(7):601–608. doi: 10.1056/NEJMoa020888. [DOI] [PubMed] [Google Scholar]
  5. Barlow J. H., Wright C. C., Williams B., Keat A. Work disability among people with ankylosing spondylitis. Arthritis Rheum. 2001 Oct;45(5):424–429. doi: 10.1002/1529-0131(200110)45:5<424::aid-art361>3.0.co;2-7. [DOI] [PubMed] [Google Scholar]
  6. Bathon J. M., Martin R. W., Fleischmann R. M., Tesser J. R., Schiff M. H., Keystone E. C., Genovese M. C., Wasko M. C., Moreland L. W., Weaver A. L. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000 Nov 30;343(22):1586–1593. doi: 10.1056/NEJM200011303432201. [DOI] [PubMed] [Google Scholar]
  7. Biasi D., Carletto A., Caramaschi P., Pacor M. L., Maleknia T., Bambara L. M. Efficacy of methotrexate in the treatment of ankylosing spondylitis: a three-year open study. Clin Rheumatol. 2000;19(2):114–117. doi: 10.1007/s100670050027. [DOI] [PubMed] [Google Scholar]
  8. Boonen A. Socioeconomic consequences of ankylosing spondylitis. Clin Exp Rheumatol. 2002 Nov-Dec;20(6 Suppl 28):S23–S26. [PubMed] [Google Scholar]
  9. Brandt J., Khariouzov A., Listing J., Haibel H., Sörensen H., Grassnickel L., Rudwaleit M., Sieper J., Braun J. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum. 2003 Jun;48(6):1667–1675. doi: 10.1002/art.11017. [DOI] [PubMed] [Google Scholar]
  10. Braun J., Bollow M., Neure L., Seipelt E., Seyrekbasan F., Herbst H., Eggens U., Distler A., Sieper J. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum. 1995 Apr;38(4):499–505. doi: 10.1002/art.1780380407. [DOI] [PubMed] [Google Scholar]
  11. Braun J., Brandt J., Listing J., Zink A., Alten R., Golder W., Gromnica-Ihle E., Kellner H., Krause A., Schneider M. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet. 2002 Apr 6;359(9313):1187–1193. doi: 10.1016/s0140-6736(02)08215-6. [DOI] [PubMed] [Google Scholar]
  12. Braun J., Pham T., Sieper J., Davis J., van der Linden Sj, Dougados M., van der Heijde D., ASAS Working Group International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis. 2003 Sep;62(9):817–824. doi: 10.1136/ard.62.9.817. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Braun J., Pincus T. Mortality, course of disease and prognosis of patients with ankylosing spondylitis. Clin Exp Rheumatol. 2002 Nov-Dec;20(6 Suppl 28):S16–S22. [PubMed] [Google Scholar]
  14. Braun J., Sieper J., Breban M., Collantes-Estevez E., Davis J., Inman R., Marzo-Ortega H., Mielants H. Anti-tumour necrosis factor alpha therapy for ankylosing spondylitis: international experience. Ann Rheum Dis. 2002 Dec;61 (Suppl 3):iii51–iii60. doi: 10.1136/ard.61.suppl_3.iii51. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Braun Juergen, Sieper Joachim. Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-alpha therapy and other novel approaches. Arthritis Res. 2002 Aug 6;4(5):307–321. doi: 10.1186/ar592. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Calin A., Garrett S., Whitelock H., Kennedy L. G., O'Hea J., Mallorie P., Jenkinson T. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol. 1994 Dec;21(12):2281–2285. [PubMed] [Google Scholar]
  17. Cañete J. D., Llena J., Collado A., Sanmartí R., Gayá A., Gratacós J., Blay M., Muñoz-Gómez J. Comparative cytokine gene expression in synovial tissue of early rheumatoid arthritis and seronegative spondyloarthropathies. Br J Rheumatol. 1997 Jan;36(1):38–42. doi: 10.1093/rheumatology/36.1.38. [DOI] [PubMed] [Google Scholar]
  18. Clegg D. O., Reda D. J., Weisman M. H., Blackburn W. D., Cush J. J., Cannon G. W., Mahowald M. L., Schumacher H. R., Jr, Taylor T., Budiman-Mak E. Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum. 1996 Dec;39(12):2004–2012. doi: 10.1002/art.1780391209. [DOI] [PubMed] [Google Scholar]
  19. Davis John C., Jr, Van Der Heijde Désirée, Braun Jurgen, Dougados Maxime, Cush John, Clegg Daniel O., Kivitz Alan, Fleischmann Roy, Inman Robert, Tsuji Wayne. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum. 2003 Nov;48(11):3230–3236. doi: 10.1002/art.11325. [DOI] [PubMed] [Google Scholar]
  20. Dougados M., vam der Linden S., Leirisalo-Repo M., Huitfeldt B., Juhlin R., Veys E., Zeidler H., Kvien T. K., Olivieri I., Dijkmans B. Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum. 1995 May;38(5):618–627. doi: 10.1002/art.1780380507. [DOI] [PubMed] [Google Scholar]
  21. Fernandez-Botran R. Soluble cytokine receptors: novel immunotherapeutic agents. Expert Opin Investig Drugs. 2000 Mar;9(3):497–514. doi: 10.1517/13543784.9.3.497. [DOI] [PubMed] [Google Scholar]
  22. Flores Diana, Marquez Javier, Garza Mario, Espinoza Luis R. Reactive arthritis: newer developments. Rheum Dis Clin North Am. 2003 Feb;29(1):37-59, vi. doi: 10.1016/s0889-857x(02)00081-9. [DOI] [PubMed] [Google Scholar]
  23. Garrett S., Jenkinson T., Kennedy L. G., Whitelock H., Gaisford P., Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994 Dec;21(12):2286–2291. [PubMed] [Google Scholar]
  24. Goodacre J. A., Mander M., Dick W. C. Patients with ankylosing spondylitis show individual patterns of variation in disease activity. Br J Rheumatol. 1991 Oct;30(5):336–338. doi: 10.1093/rheumatology/30.5.336. [DOI] [PubMed] [Google Scholar]
  25. Gorman Jennifer D., Sack Kenneth E., Davis John C., Jr Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med. 2002 May 2;346(18):1349–1356. doi: 10.1056/NEJMoa012664. [DOI] [PubMed] [Google Scholar]
  26. Gran J. T., Skomsvoll J. F. The outcome of ankylosing spondylitis: a study of 100 patients. Br J Rheumatol. 1997 Jul;36(7):766–771. doi: 10.1093/rheumatology/36.7.766. [DOI] [PubMed] [Google Scholar]
  27. Gratacós J., Collado A., Filella X., Sanmartí R., Cañete J., Llena J., Molina R., Ballesta A., Muñoz-Gómez J. Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity. Br J Rheumatol. 1994 Oct;33(10):927–931. doi: 10.1093/rheumatology/33.10.927. [DOI] [PubMed] [Google Scholar]
  28. Grom A. A., Murray K. J., Luyrink L., Emery H., Passo M. H., Glass D. N., Bowlin T., Edwards C., 3rd Patterns of expression of tumor necrosis factor alpha, tumor necrosis factor beta, and their receptors in synovia of patients with juvenile rheumatoid arthritis and juvenile spondylarthropathy. Arthritis Rheum. 1996 Oct;39(10):1703–1710. doi: 10.1002/art.1780391013. [DOI] [PubMed] [Google Scholar]
  29. Kennedy L. G., Edmunds L., Calin A. The natural history of ankylosing spondylitis. Does it burn out? J Rheumatol. 1993 Apr;20(4):688–692. [PubMed] [Google Scholar]
  30. Lovell D. J., Giannini E. H., Reiff A., Cawkwell G. D., Silverman E. D., Nocton J. J., Stein L. D., Gedalia A., Ilowite N. T., Wallace C. A. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med. 2000 Mar 16;342(11):763–769. doi: 10.1056/NEJM200003163421103. [DOI] [PubMed] [Google Scholar]
  31. Maksymowych Walter P., Breban Maxime, Braun J. Ankylosing spondylitis and current disease-controlling agents: do they work? Best Pract Res Clin Rheumatol. 2002 Sep;16(4):619–630. [PubMed] [Google Scholar]
  32. Maksymowych Walter P., Jhangri Gian S., Lambert Robert G., Mallon Cathy, Buenviaje Heidi, Pedrycz Ewa, Luongo Rolfe, Russell Anthony S. Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety. J Rheumatol. 2002 May;29(5):959–965. [PubMed] [Google Scholar]
  33. Maksymowych Walter P. Novel therapies in the treatment of spondyloarthritis. Expert Opin Investig Drugs. 2002 Jul;11(7):937–946. doi: 10.1517/13543784.11.7.937. [DOI] [PubMed] [Google Scholar]
  34. Marzo-Ortega H., McGonagle D., O'Connor P., Emery P. Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study. Arthritis Rheum. 2001 Sep;44(9):2112–2117. doi: 10.1002/1529-0131(200109)44:9<2112::AID-ART363>3.0.CO;2-H. [DOI] [PubMed] [Google Scholar]
  35. Mease P. J., Goffe B. S., Metz J., VanderStoep A., Finck B., Burge D. J. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000 Jul 29;356(9227):385–390. doi: 10.1016/S0140-6736(00)02530-7. [DOI] [PubMed] [Google Scholar]
  36. Moreland L. W., Margolies G., Heck L. W., Jr, Saway A., Blosch C., Hanna R., Koopman W. J. Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: toxicity and dose finding trial in refractory rheumatoid arthritis. J Rheumatol. 1996 Nov;23(11):1849–1855. [PubMed] [Google Scholar]
  37. Moreland L. W., Schiff M. H., Baumgartner S. W., Tindall E. A., Fleischmann R. M., Bulpitt K. J., Weaver A. L., Keystone E. C., Furst D. E., Mease P. J. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med. 1999 Mar 16;130(6):478–486. doi: 10.7326/0003-4819-130-6-199903160-00004. [DOI] [PubMed] [Google Scholar]
  38. Ringsdal V. S., Andreasen J. J. Ankylosing spondylitis--experience with a self administered questionnaire: an analytical study. Ann Rheum Dis. 1989 Nov;48(11):924–927. doi: 10.1136/ard.48.11.924. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Roychowdhury B., Bintley-Bagot S., Bulgen D. Y., Thompson R. N., Tunn E. J., Moots R. J. Is methotrexate effective in ankylosing spondylitis? Rheumatology (Oxford) 2002 Nov;41(11):1330–1332. doi: 10.1093/rheumatology/41.11.1330. [DOI] [PubMed] [Google Scholar]
  40. Taylor A. L., Balakrishnan C., Calin A. Reference centile charts for measures of disease activity, functional impairment, and metrology in ankylosing spondylitis. Arthritis Rheum. 1998 Jun;41(6):1119–1125. doi: 10.1002/1529-0131(199806)41:6<1119::AID-ART20>3.0.CO;2-0. [DOI] [PubMed] [Google Scholar]
  41. Toussirot E., Lafforgue P., Boucraut J., Despieds P., Schiano A., Bernard D., Acquaviva P. C. Serum levels of interleukin 1-beta, tumor necrosis factor-alpha, soluble interleukin 2 receptor and soluble CD8 in seronegative spondylarthropathies. Rheumatol Int. 1994;13(5):175–180. doi: 10.1007/BF00390264. [DOI] [PubMed] [Google Scholar]
  42. Van Den Bosch Filip, Kruithof Elli, Baeten Dominique, Herssens Annemie, de Keyser Filip, Mielants Herman, Veys Eric M. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum. 2002 Mar;46(3):755–765. doi: 10.1002/art.511. [DOI] [PubMed] [Google Scholar]
  43. Ward M. M. Health-related quality of life in ankylosing spondylitis: a survey of 175 patients. Arthritis Care Res. 1999 Aug;12(4):247–255. [PubMed] [Google Scholar]
  44. Ward Michael M. Functional disability predicts total costs in patients with ankylosing spondylitis. Arthritis Rheum. 2002 Jan;46(1):223–231. doi: 10.1002/1529-0131(200201)46:1<223::AID-ART498>3.0.CO;2-#. [DOI] [PubMed] [Google Scholar]
  45. Will R., Edmunds L., Elswood J., Calin A. Is there sexual inequality in ankylosing spondylitis? A study of 498 women and 1202 men. J Rheumatol. 1990 Dec;17(12):1649–1652. [PubMed] [Google Scholar]
  46. van Tubergen Astrid, Coenen Jolanda, Landewé Robert, Spoorenberg Anneke, Chorus Astrid, Boonen Annelies, van der Linden Sjef, van der Heijde Désirée. Assessment of fatigue in patients with ankylosing spondylitis: a psychometric analysis. Arthritis Rheum. 2002 Feb;47(1):8–16. doi: 10.1002/art1.10179. [DOI] [PubMed] [Google Scholar]
  47. van der Linden S., Valkenburg H. A., Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984 Apr;27(4):361–368. doi: 10.1002/art.1780270401. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES